Friday, 06 Dec 2019

PsA/SpA

Date Typesort ascending Title Save
29 Jun 2018 Social European Commission has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of adults with active psoriatic arthritis (PsA) with an inadequate response to DMARDs https://t.co/G6YYXSuUyQ
24 Feb 2017 Social Study of >43K Pso, PsA, AS pts shows 14-34% increase risk for depression; but not for suicide or suicidal ideation. https://t.co/STsQikW5pN
18 Jun 2015 Social Arthritis mutilans review & defined:digital telescoping/shortening, flail jts, xray resorption, pencil-in-cup change http://t.co/PXq9iPBQyZ
17 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/ffsAfiaU70
17 Feb 2017 Social RT @DrRachelTate: RAPID3 as a potential useful tool for PsA. Arthur Kavanaugh, MD and Eric Ruderman, MD #rwcs2017 @RWCSmtg @RheumNow https:…
22 Oct 2018 Social RT @japaoli19: Abstract 1631 20% incidence of uveitis in SpA with IBD phenotype having the highest incidence #ACR18 @rheumnow https://t.co…
29 Aug 2019 Social Amgen Inc will buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year. https://t.co/0DkfUG5alt
12 Nov 2019 Social RT @DrPetryna: @RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media th…
05 Nov 2017 Social RT @japaoli19: Low dose CT detects more spinal progression vs xray in AS measured by ct syndesmophyte sc #582 #ACR17 @rheumnow https://t.…
27 Jun 2016 Social RAPID3 gives similar outcome info to BASDAI and ASDAS in a cross sectional study of 85 AS patients https://t.co/uIfXJpB5s3
09 Sep 2018 Social Excellent open review of obesity's influence on disease onset (RA, PsA), pathogenesis, disease progression, functional consequences and treatment interference. https://t.co/xaOkBrWDR4
18 Apr 2017 Social Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ https://t.co/2UcTOZKhYf
02 Oct 2015 Social Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz http://t.co/akU4NR3Etg
15 Oct 2019 Social Followup of 783 tofacitinib‐treated psoriatic arthritis patients finds increases in LDL and HDL 9% to 14% after 3 and 6 months of therapy with a low risk of HTN or MACE events https://t.co/fh6UbmF3lr
13 Nov 2019 Social RT @DrKanikaMonga: Abstract #0626 Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from…
06 Nov 2017 Social Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts… https://t.co/O1xSQ6nafD
07 Oct 2016 Social Am I wrong?Otezla warnings overstate risk of depression % wt loss; yet understate diarrhea 9% & D/C for diarrhea <2% https://t.co/UwFi8b6txr
25 May 2017 Social Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
30 Jul 2015 Social PSOLAR registry Infection risk w/ age, DM, smoking, prior Infx, INFLX, ADA. Low rate w/ Stelara 0.83 & ETN 1.47/100PY http://t.co/OxTbxe2HN9
22 Mar 2018 Social FDA Approves Ilumya (tildrakizumab for Moderate-to-Severe Plaque Psoriasis. It binds p19 subunit of IL-23, inhibiting binding to IL-23 receptor. Given as 100 mg sc at Wk 0, 4 & q 12wks; 2nd IL-23 inhib approved for Pso. https://t.co/q9bQTVqN0t